Gene therapy for diabetes: Metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model

A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION

Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751 · see citing works

International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels

Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126 · see citing works

Adipose Tissue as an Endocrine Organ

Kershaw, E. E., & Flier, J. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0395 · Cited by 5,522 · see citing works

The Physiology of Glucagon-like Peptide 1

Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · see citing works

Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.

Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · see citing works

Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion.

Hohmeier, H. E., Mulder, H., Chen, G., Henkel-Rieger, R., Prentki, M., & Newgard, C. B. (2000) · Diabetes · doi:10.2337/diabetes.49.3.424 · Cited by 922 · see citing works

Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans

Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 916 · see citing works

Glucagon and regulation of glucose metabolism

Jiang, G., & Zhang, B. B. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00492.2002 · Cited by 905 · see citing works

Hepatic Fatty Acid Transporter Cd36 Is a Common Target of LXR, PXR, and PPARγ in Promoting Steatosis

Zhou, J., Febbraio, M., Wada, T., Zhai, Y., Kuruba, R., He, J., Lee, J. H., Khadem, S., Ren, S., Li, S., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.11.037 · Cited by 608 · see citing works

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

Ding, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557 · see citing works

International Union of Pharmacology. XXXV. The Glucagon Receptor Family

Mayo, K. E., Miller, L. J., BATAILLE, D., Dalle, S., Göke, B., Thorens, B., & Drucker, D. J. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.6 · Cited by 507 · see citing works

Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes

Kim, D. S., MacConell, L., Zhuang, D., Kothare, P. A., TRAUTMANN, M. E., Fineman, M. S., & Taylor, K. (2007) · Diabetes Care · doi:10.2337/dc06-2375 · Cited by 447 · see citing works

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

Young, A. A., Gedulin, B. R., Bhavsar, S., Bodkin, N., Jodka, C., Hansen, B., & Denaro, M. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1026 · Cited by 440 · see citing works

Hepatic Stearoyl-CoA Desaturase-1 Deficiency Protects Mice from Carbohydrate-Induced Adiposity and Hepatic Steatosis

Miyazaki, M., Flowers, M. T., Sampath, H., Chu, K., Otzelberger, C., Liu, X., & Ntambi, J. M. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.014 · Cited by 426 · see citing works

Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure

Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.063 · Cited by 372 · see citing works

Increased expression of PPARγ in high fat diet-induced liver steatosis in mice

Inoue, M., Ohtake, T., Motomura, W., Takahashi, N., Hosoki, Y., Miyoshi, S., Suzuki, Y., Saito, H., Kohgo, Y., & Okumura, T. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.070 · Cited by 357 · see citing works

Double Incretin Receptor Knockout (DIRKO) Mice Reveal an Essential Role for the Enteroinsular Axis in Transducing the Glucoregulatory Actions of DPP-IV Inhibitors

Hansotia, T., Baggio, L. L., Delmeire, D., Hinke, S. A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J. J., Schuit, F., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1326 · Cited by 309 · see citing works

Decreased Hepatic Triglyceride Accumulation and Altered Fatty Acid Uptake in Mice with Deletion of the Liver Fatty Acid-binding Protein Gene

Newberry, E. P., Xie, Y., Kennedy, S., Han, X., Buhman, K. K., Luo, J., Gross, R. W., & Davidson, N. O. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m309377200 · Cited by 305 · see citing works

SREBPs: the crossroads of physiological and pathological lipid homeostasis

Raghow, R., Yellaturu, C. R., Deng, X., Park, E. A., & Elam, M. B. (2008) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2007.10.009 · Cited by 304 · see citing works

Diet-induced Obesity Alters AMP Kinase Activity in Hypothalamus and Skeletal Muscle

Martin, T. L., Alquier, T., Asakura, K., Furukawa, N., Preitner, F., & Kahn, B. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512831200 · Cited by 283 · see citing works

Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease

Qureshi, K. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i26.3540 · Cited by 282 · see citing works

Exenatide (Exendin-4) Improves Insulin Sensitivity and β-Cell Mass in Insulin-Resistant Obesefa/faZucker Rats Independent of Glycemia and Body Weight

Gedulin, B. R., Nikoulina, S. E., Smith, P. A., Gedulin, G., Nielsen, L. L., Baron, A., Parkes, D. G., & Young, A. A. (2004) · Endocrinology · doi:10.1210/en.2004-1349 · Cited by 241 · see citing works

Small-molecule agonists for the glucagon-like peptide 1 receptor

Knudsen, L. B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J. T., Holst, J. J., Jeppesen, C. B., Johnson, M. D., de Jong, J. C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605701104 · Cited by 232 · see citing works

Long-Term Treatment of Glucagon-Like Peptide-1 Analog Exendin-4 Ameliorates Diabetic Nephropathy through Improving Metabolic Anomalies in db/db Mice

Park, C. W., Kim, H. W., Ko, S. H., Lim, J. H., Ryu, G. R., Chung, H. W., Han, S. W., Shin, S. J., Bang, B. K., Breyer, M. D., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006070778 · Cited by 218 · see citing works

Liraglutide, a Long-Acting Glucagon-Like Peptide-1 Analog, Reduces Body Weight and Food Intake in Obese Candy-Fed Rats, Whereas a Dipeptidyl Peptidase-IV Inhibitor, Vildagliptin, Does Not

Raun, K., von Voss, P., Gotfredsen, C. F., Golozoubova, V., Rolin, B. C., & Knudsen, L. B. (2006) · Diabetes · doi:10.2337/db06-0565 · Cited by 207 · see citing works

Leptin Regulation of the Anorexic Response to Glucagon-Like Peptide-1 Receptor Stimulation

Williams, D. L., Baskin, D. G., & Schwartz, M. W. (2006) · Diabetes · doi:10.2337/db06-0558 · Cited by 178 · see citing works

A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db / db mice

Chen, D., Liao, J., Li, N., Zhou, C., Liu, Q., Wang, G., Zhang, R., Zhang, S., Lin, L., Chen, K., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610173104 · Cited by 171 · see citing works

Glucagon-Like Peptide-1 Gene Therapy in Obese Diabetic Mice Results in Long-Term Cure of Diabetes by Improving Insulin Sensitivity and Reducing Hepatic Gluconeogenesis

Lee, Y.-S., Shin, S., Shigihara, T., Hahm, E., Liu, M.-J., Han, J., Yoon, J.-W., & Jun, H.-S. (2007) · Diabetes · doi:10.2337/db06-1182 · Cited by 158 · see citing works

Glucagon-like peptide 1-(7–36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats

Schick, R., Zimmermann, J., Walde, T. V., & SCHUSDZIARRA, V. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00479.2002 · Cited by 152 · see citing works

An Albumin-Exendin-4 Conjugate Engages Central and Peripheral Circuits Regulating Murine Energy and Glucose Homeostasis

Baggio, L. L., Huang, Q., Cao, X., & Drucker, D. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.017 · Cited by 137 · see citing works

Leptin interacts with glucagon‐like peptide‐1 neurons to reduce food intake and body weight in rodents

Goldstone, A. P., Mercer, J. G., Gunn, I., Moar, K. M., Edwards, C. M. B., Rossi, M., Howard, J. K., Rasheed, S., Turton, M. D., Small, C. J., et al. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01103-4 · Cited by 131 · see citing works

The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans

Flint, A., Raben, A., Jf, R., Holst, J. J., & Astrup, A. V. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801126 · Cited by 120 · see citing works

A High-Efficiency Cre/loxP-Based System for Construction of Adenoviral Vectors

Parks, R. J., Cummings, D. T., Evelegh, C. M., Sankar, U., & Graham, F. L. (1999) · Human Gene Therapy · doi:10.1089/10430349950016708 · Cited by 110 · see citing works

Cell signalling of the GLP-1 action in rat liver

Redondo, A. (2003) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(03)00146-1 · Cited by 96 · see citing works

Exenatide prevents fat‐induced insulin resistance and raises adiponectin expression and plasma levels

Li, L., Yang, G., Li, Q., Tan, X., Liu, H., Tang, Y., & Boden, G. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00832.x · Cited by 90 · see citing works

PPAR? in the pathogenesis of fatty liver disease

Rao, M. S., & Reddy, J. K. (2004) · Hepatology · doi:10.1002/hep.20453 · Cited by 87 · see citing works

Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1

IDRIS, I. R., Patiag, D., Gray, S., & Donnelly, R. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00924-8 · Cited by 86 · see citing works

Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans

Pannacciulli, N., Bunt, J. C., Koška, J., Bogardus, C., & Krakoff, J. A. (2006) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/84.3.556 · Cited by 85 · see citing works

Effects of insulin resistance on substrate utilization during exercise in overweight women

Braun, B., Sharoff, C., Chipkin, S. R., & Beaudoin, F. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00231.2004 · Cited by 84 · see citing works

Dose–response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats

Gedulin, B. R., Smith, P., Prickett, K. S., Tryon, M. S., Barnhill, S. D., Reynolds, J., Nielsen, L. L., Parkes, D. G., & Young, A. A. (2005) · Diabetologia · doi:10.1007/s00125-005-1795-2 · Cited by 77 · see citing works

PPARα in the pathogenesis of fatty liver disease

Rao, S. M., & Reddy, J. K. (2004) · Hepatology · doi:10.1002/hep.1840400405 · Cited by 76 · see citing works

Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice

Kumar, M., Hunag, Y. P., Glinka, Y., Prud’homme, G. J., & Wang, Q. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302836 · Cited by 70 · see citing works

Extrapancreatic Effects of GIP and GLP-1

Vella, A. V., & Rizza, R. A. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-82617 · Cited by 50 · see citing works

Incretin-based therapies: mimetics versus protease inhibitors

Brubaker, P. L. (2007) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2007.06.005 · Cited by 49 · see citing works

GLP-1 gene delivery for the treatment of type 2 diabetes

Oh, S., Lee, M., Ko, K. S., Choi, S.-A., & Kim, S. W. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00036-4 · Cited by 48 · see citing works

Ectopic expression of glucagon-like peptide 1 for gene therapy of type II diabetes

Parsons, G. B., Souza, D. W., Wu, H., Yu, D., Wadsworth, S. G., Gregory, R. J., & Armentano, D. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302842 · Cited by 44 · see citing works

Sustained Expression of Exendin-4 Does Not Perturb Glucose Homeostasis, β-Cell Mass, or Food Intake in Metallothionein-Preproexendin Transgenic Mice

Baggio, L. L., Adatia, F. A., Bock, T. G., Brubaker, P. L., & Drucker, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005119200 · Cited by 40 · see citing works

Sustained phenotypic correction in a mouse model of hypoalphalipoproteinemia with a helper-dependent adenovirus vector

Oka, K., Belalcazar, L. M., Dieker, C., Nour, E. A., Nuno-Gonzalez, P., Paul, A., Cormier, S., Shin, J.-K., Finegold, M. J., & Chan, L. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302819 · Cited by 38 · see citing works

Insulin Action in the Double Incretin Receptor Knockout Mouse

Ayala, J. E., Bracy, D. P., Hansotia, T., Flock, G. B., Seino, Y., Wasserman, D. H., & Drucker, D. J. (2007) · Diabetes · doi:10.2337/db07-0704 · Cited by 36 · see citing works

Lymphocytic Infiltration and Immune Activation in Metallothionein Promoter–Exendin-4 (MT-Exendin) Transgenic Mice

Baggio, L. L., Holland, D. P., Wither, J., & Drucker, D. J. (2006) · Diabetes · doi:10.2337/db05-1502 · Cited by 21 · see citing works

Blockade of central GLP-1 receptors prevents CART-induced hypophagia and brain c-Fos expression

Aja, S. M., Ewing, C., Lin, J. M., Hyun, J., & Moran, T. H. (2005) · Peptides · doi:10.1016/j.peptides.2005.07.003 · Cited by 20 · see citing works

Helper‐Dependent Adenoviral Vectors

Oka, K., & Chan, L. (2005) · Current Protocols in Molecular Biology · doi:10.1002/0471142727.mb1624s69 · Cited by 12 · see citing works

Helper‐Dependent Adenoviral Vectors

Oka, K., & Chan, L. (2004) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg1213s43 · Cited by 5 · see citing works

Current Progress in Gene Delivery Technology Based on Chemical Methods and Nano-Carriers

Jin, L., Zeng, X., Liu, M., Deng, Y., & He, N. (2014) · Theranostics · doi:10.7150/thno.6914 · Cited by 388 · see citing works

Advances in Non-Viral DNA Vectors for Gene Therapy

Hardee, C. L., Arévalo-Soliz, L., Hornstein, B. D., & Zechiedrich, L. (2017) · Genes · doi:10.3390/genes8020065 · Cited by 329 · see citing works

GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives

Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286 · see citing works

Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice

Trevaskis, J. L., Griffin, P. S., Wittmer, C., Neuschwander-Tetri, B. A., Brunt, E. M., Dolman, C. S., Erickson, M. R., Napora, J., Parkes, D. G., & Roth, J. D. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00476.2011 · Cited by 277 · see citing works

Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: A prospective randomized clinical trial using magnetic resonance imaging and spectroscopy

Dutour, A., Abdesselam, I., Ancel, P., Kober, F., Mrad, G., Darmon, P., Ronsin, O., Pradel, V., Lesavre, N., Martin, J. C., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12680 · Cited by 262 · see citing works

Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression

Chung, L. T. K., Hosaka, T., Yoshida, M., Harada, N., Sakaue, H., Sakai, T., & Nakaya, Y. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.10.015 · Cited by 160 · see citing works

Restoration of leptin responsiveness in diet‐induced obese mice using an optimized leptin analog in combination with exendin‐4 or FGF21

Müller, T. D., Sullivan, L. M., Habegger, K., Yi, C., Kabra, D., Grant, E., Ottaway, N., Krishna, R., Holland, J., Hembree, J., et al. (2012) · Journal of Peptide Science · doi:10.1002/psc.2408 · Cited by 156 · see citing works

The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy

Liu, J., Xu, Y., Hu, Y., & Wang, G. (2014) · Metabolism · doi:10.1016/j.metabol.2014.11.009 · Cited by 137 · see citing works

Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis

Tomás, E., & Habener, J. F. (2009) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2009.11.007 · Cited by 135 · see citing works

Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes

Sathyanarayana, P., Jogi, M., Muthupillai, R., Krishnamurthy, R., Samson, S. L., & Bajaj, M. (2011) · Obesity · doi:10.1038/oby.2011.152 · Cited by 124 · see citing works

Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial

Samson, S. L., Sathyanarayana, P., Jogi, M., Gonzalez, E. V., Gutierrez, A., Krishnamurthy, R., Muthupillai, R., Chan, L., & Bajaj, M. (2011) · Diabetologia · doi:10.1007/s00125-011-2317-z · Cited by 110 · see citing works

Helper-dependent adenoviral vectors for liver-directed gene therapy

Brunetti‐Pierri, N., & Ng, P. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr143 · Cited by 81 · see citing works

Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway

FILOZOF, C. M., Goldstein, B. J., Williams, R. N., & Sanyal, A. J. (2015) · Drugs · doi:10.1007/s40265-015-0437-3 · Cited by 76 · see citing works

Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH

Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66 · see citing works

The future of incretin‐based therapy: novel avenues—novel targets

Åhrén, B. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01457.x · Cited by 63 · see citing works

Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice

Jouihan, H., Will, S., Guionaud, S., Boland, M. L., Oldham, S., Ravn, P., Celeste, A., & Trevaskis, J. L. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.09.001 · Cited by 59 · see citing works

GLP‐1 receptor agonists: effects on the progression of non‐alcoholic fatty liver disease

Liu, J., Wang, G., Jia, Y., & Xu, Y. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2580 · Cited by 48 · see citing works

Glucagon‐like peptide‐1(9‐36)amide metabolite inhibits weight gain and attenuates diabetes and hepatic steatosis in diet‐induced obese mice

Tomás, E., Wood, J. A., Stanojevic, V., & Habener, J. F. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01316.x · Cited by 48 · see citing works

GLP-1-derived nonapeptide GLP-1(28–36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice

Tomás, E., Wood, J. A., Stanojevic, V., & Habener, J. F. (2011) · Regulatory Peptides · doi:10.1016/j.regpep.2011.04.006 · Cited by 45 · see citing works

Exenatide Improves Hypertension in a Rat Model of the Metabolic Syndrome

Laugero, K. D., Stonehouse, A. H., Guss, S., Landry, J., Vu, C., & Parkes, D. G. (2009) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2008.0095 · Cited by 45 · see citing works

Potential of incretin-based therapies for non-alcoholic fatty liver disease

Samson, S. L., & Bajaj, M. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.12.005 · Cited by 44 · see citing works

New Insights from Rodent Models of Fatty Liver Disease

Maher, J. J. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3749 · Cited by 43 · see citing works

Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes

Havranek, B., Loh, R., Torre, B., Redfield, R. L., & Halegoua-DeMarzio, D. L. (2025) · Scientific Reports · doi:10.1038/s41598-025-89408-z · Cited by 40 · see citing works

Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease

Blaslov, K. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7356 · Cited by 38 · see citing works

Effects of Sitagliptin on Nonalcoholic Fatty Liver Disease in Diet-Induced Obese Rats

Beysel, S., Değertekin, C. K., Yılmaz, G., Çakır, N., Arslan, M., & Törüner, F. B. (2013) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2012.0128 · Cited by 36 · see citing works

Exendin-4 Improves Blood Glucose Control in Both Young and Aging Normal Non-Diabetic Mice, Possible Contribution of Beta Cell Independent Effects

Fan, R., Kang, Z., He, L., Chan, J. C. N., & Xu, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020443 · Cited by 31 · see citing works

Gene therapy for obesity: progress and prospects.

Gao, M., & Liu, D. (2014) · PubMed · Cited by 30 · see citing works

Exenatide Activates the APPL1-AMPK-PPARαAxis to Prevent Diabetic Cardiomyocyte Apoptosis

XiaoTian, L., Wu, Q., XiaGuang, G., WuQuan, D., Chen, B., & ZiWen, L. (2015) · Journal of Diabetes Research · doi:10.1155/2016/4219735 · Cited by 25 · see citing works

Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus

Hu, Y., Liu, J., Zhang, H., Xu, Y., Hong, T., & Wang, G. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.04.005 · Cited by 22 · see citing works

GLP-1-mediated gene therapy approaches for diabetes treatment

Tasyurek, H. M., Altunbaş, H., Canatan, H., Griffith, T. S., & Şanlıoğlu, S. (2014) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2014.7 · Cited by 21 · see citing works

Glucagon-Like Peptide-1 Gene Therapy

Rowzee, A. M., Cawley, N. X., Chiorini, J. A., & Pasquale, G. D. (2011) · Experimental Diabetes Research · doi:10.1155/2011/601047 · Cited by 20 · see citing works

Sustained Exendin-4 Secretion through Gene Therapy Targeting Salivary Glands in Two Different Rodent Models of Obesity/Type 2 Diabetes

Pasquale, G. D., Dicembrini, I., Raimondi, L., Pagano, C., Egan, J. M., Cozzi, A., Cinci, L., Loreto, A., Manni, M. E., Berretti, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040074 · Cited by 17 · see citing works

Guanylin and uroguanylin mRNA expression is increased following Roux-en-Y gastric bypass, but guanylins do not play a significant role in body weight regulation and glycemic control

Fernandez-Cachon, M. L., Pedersen, S. L., Rigbolt, K. T. G., Zhang, C., Fabricius, K., Hansen, H. H., Elster, L., Fink, L. N., Schäfer, M., Rhee, N. A., et al. (2017) · Peptides · doi:10.1016/j.peptides.2017.12.024 · Cited by 17 · see citing works

Adipokines and Lipoproteins: Modulation by Antihyperglycemic and Hypolipidemic Agents

Rizvi, A. A., Nikolić, D., Sallam, H. S., Montalto, G., Rizzo, M., & Abate, N. I. (2013) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2013.0090 · Cited by 15 · see citing works

Pulsed Electric Fields Alter Expression of NF-κB Promoter-Controlled Gene

Kavaliauskaitė, J., Kazlauskaitė, A., Lazutka, J. R., Mozoļevskis, G., & Stirkė, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010451 · Cited by 15 · see citing works

Effect of exenatide therapy on hepatic fat quantity and hepatic biomarkers in type 2 diabetic patients

Blaslov, K., Zibar, K., Bulum, T., & Duvnjak, L. S. (2013) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2013.10.013 · Cited by 14 · see citing works

Treatment of diabetes with glucagon-like peptide-1 gene therapy

Riedel, M. J., & Kieffer, T. J. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.532786 · Cited by 13 · see citing works

Exenatide reduces cardiomyocyte apoptosis by stimulating adiponectin secretion and activating APPL1-AMPK-PPARα axis

Lei, X., Wu, Q., Leng, W., Wu, M., Chen, L., & Liang, Z. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.06.17 · Cited by 10 · see citing works

Polymer-Based Delivery of Glucagon-Like Peptide-1 for the Treatment of Diabetes

Kim, P., & Kim, S. W. (2012) · ISRN Endocrinology · doi:10.5402/2012/340632 · Cited by 9 · see citing works

Effect of recombinant adenovirus coding for endomorphin-2 on neuropathic pain in rats.

Wu, F., Xu, X., Miao, X., Chen, J., Sun, Y., & Yu, W. (2012) · PubMed Central · Cited by 8 · see citing works

Direct actions of GLP-1 analogues on AMP-activated protein kinase activity are distinct from cyclic AMP accumulation

Samson, S. L., & Bajaj, M. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.10.032 · Cited by 7 · see citing works

Targeted in vivo gene integration of a secretion-enabled GLP-1 receptor agonist reverses diet-induced non-genetic obesity and pre-diabetes

Hirose, J., Aizawa, E., Yamamoto, S., Iwai, S., & Suzuki, K. (2025) · Communications Medicine · doi:10.1038/s43856-025-00959-8 · Cited by 4 · see citing works

Reversal of Obesity and Metabolic Disorders by Exercise in High-Fat Diet-Induced Obese C57BL/6 mice

Mahmud, I. A., & Al-Domi, H. A. (2014) · Jordan Journal of Agricultural Sciences · Cited by 3 · see citing works

Codon-optimized FAM132b gene therapy prevents dietary obesity by blockading adrenergic response and insulin action

Qi, Z., Xia, J., Xue, X., Liu, W., Huang, Z., Zhang, X., Zou, Y., Liu, J., Li, X., Li, X., et al. (2022) · International Journal of Obesity · doi:10.1038/s41366-022-01189-x · Cited by 3 · see citing works

Traitement de la stéatose et de la stéatohépatite non alcoolique par les traitements antidiabétiques

Vergès, B. L. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30166-9 · Cited by 2 · see citing works

Helper-Dependent Adenoviral Vectors for Gene Therapy

Brunetti‐Pierri, N., & Ng, P. (2015) · CRC Press eBooks · doi:10.1201/b18002-5 · Cited by 2 · see citing works

Effectiveness and Safety of Once-Weekly Semaglutide in Japanese Patients with Type 2 Diabetes: A Retrospective Observational Multicenter Study (ORIGAMI Study)

Iwata, Y., Yoshikawa, F., Saito, M., Fuchigami, A., Sato, G. E., Saiki, A., Ichijyo, T., Sato, N., Ohashi, T., Hirose, T., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01790-z · Cited by 1 · see citing works

The role of glucagon-like peptide-1 on food intake, glucokinase expression and fatty acid metabolism

Zhang, H. (2009) · doi:10.31390/gradschool_theses.3765 · Cited by 1 · see citing works

Other Future Directions

Chen, S., Rajagopal, J., Zhou, Q., Melton, D. A., Koh, A., Senior, P. A., Shapiro, A. M. J., Barbu, A. R., & Welsh, N. (2010) · doi:10.1002/9781444324808.ch61

Glucagon-like peptide-1 in nonalcoholic steatohepatitis

Armstrong, M. J. (2014) · University of Birmingham Institutional Research Archive (University of Birmingham)

Development of a Protocol for Selection of GenesFit for the In Vivo Knockdown Method and its Application to Insulin Receptor Substrate Genesin Mice

Saito, M., Kakutani, Y., Kaburagi, M., Funabashi, H., & Matsuoka, H. (2013) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.62.117

Antiobesity Effect of Peripheral Exendin-4 and/or Exercise in High-Fat Diet-Induced Obese C57bl/6 Mice

Al-Domi, H. A., & Mahmud, I. A. (2016) · Pakistan Journal of Nutrition · doi:10.3923/pjn.2016.379.385

Codon-Optimized FAM132b Prevents Diet-Induced Obesity by Modulating Adrenergic Response and Insulin ActionPreprint

Qi, Z., Xia, J., Xue, X., Liu, W., Huang, Z., Zhang, X., Zou, Y., Liu, J., Liu, J., Li, X., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3708518

The pathophysiology of gut–liver connection

Maroni, L., Fianchi, F., Miele, L., & Svegliati‐Baroni, G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821927-0.00002-4

Systems of adenoviral gene transfer vectors moving into their fourth generation

Yan, Q., Cull, J. W., Tarbet, E. B., & Staerz, U. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-89821-8.00002-4

Sustained Exendin-4 Secretion through Gene Therapy Targeting Salivary Glands in Two Different Rodent Models of Obesity/Type 2 Diabetes

Pasquale, G. D., Dicembrini, I., Raimondi, L., Pagano, C., Egan, J. M., Cozzi, A., Cinci, L., Loreto, A., Manni, M. E., Berretti, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040074 · Cited by 17 · see citing works

“Persistente secrezione di Exendin-4, un agonista recettoriale del Glucagon-like peptide-1, mediante terapia genica mediata da Adeno-associated Viruses, su ghiandole salivari di roditori in due differenti modelli di obesità/diabete tipo 2”

Dicembrini, I. (2013) · Florence Research (University of Florence)

Double-strand adeno-associated virus-mediated exendin-4 expression in salivary glands is efficient in a diabetic rat model

Wang, J., Wang, F., Xu, J., Ding, S., & Guo, Y. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.12.006 · Cited by 8 · see citing works

Effects of exendin‐4 on islets from type 2 diabetes patients

Lupi, R., Mancarella, R., Guerra, S. D., Bugliani, M., Prato, S. D., Boggi, U., Mosca, F., Filipponi, F., & Marchetti, P. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00838.x · Cited by 47 · see citing works

A novel gene therapy platform for the treatment of type 2 diabetes and obesity

Lourie, J., Goraltchouk, A., Hollander, J. M., BERGER, N. J. A., Rosen, H. G., Fujishiro, A. A., Luppino, F., Seregin, A., Rhym, L. H., & Zou, K. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102739 · Cited by 4 · see citing works